Vera A Bittner MD
Nuclear Cardiology, Preventive Cardiology, Exercise Physiology and Cardiac Rehabilitation, Cardiac Critical Care
Professor, Medicine, University of Alabama School of Medicine
Join to View Full Profile
2000 6th Ave SBirmingham, AL 35233
Phone+1 205-934-9999
Dr. Bittner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Section Head, Preventive Cardiology
Education & Training
University of Alabama Medical CenterFellowship, Cardiovascular Disease, 1984 - 1987
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1981 - 1984
University of South Alabama College of MedicineClass of 1981
Certifications & Licensure
AL State Medical License 1984 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Cor...P Gabriel Steg, Michael Szarek, J Wouter Jukema, Deepak L Bhatt, Vera A Bittner
Circulation. 2025-04-08 - Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial.Gregory G Schwartz, Michael Szarek, J Wouter Jukema, Christa M Cobbaert, Esther Reijnders
Diabetes Care. 2025-04-01 - Body Mass Index, Comorbidities, and Ambulatory Care Visits: The REGARDS Study.Emily B Levitan, Aowen Zhu, Vera Bittner, Todd M Brown, Michael E Farkouh
Journal of the American Heart Association. 2025-04-01
Journal Articles
- Original Investigations Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES TrialGregory G Schwartz, Vera A Bittner, ScienceDirect
- Alirocumab and Cardiovascular Outcomes After Acute Coronary SyndromeVera A Bittner, Kenneth W Mahaffey, Deepak L Bhatt, Robert A Harrington, Gregory G Schwartz, Matthew T Roe, The New England Journal of Medicine
- Do Not Smoke, Eat Healthy, and ExerciseVera Bittner, MD, JACC: Cardiovascular Imaging
Lectures
- Lipoprotein(a) Lowering by Alirocumab Contributes to Total Events Reduction Independent of Low-Density Lipoprotein Cholesterol in the ODYSSEY OUTCOMES Trial2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Late-Breaking Clinical Trials2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Hypertension Management Hypercharged: The Devil is in the Details2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
- Join now to see all
Authored Content
- Do Not Smoke, Eat Healthy, and ExerciseNovember 2018
- Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United StatesApril 2018
- Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United StatesApril 2018
Press Mentions
Lp(A) Packs a More Powerful Atherogenic Punch Than LDLJanuary 29th, 2024- Cholesterol Medications, Flu Shots and Heart Failure: Day 2 at ACC.22April 4th, 2022
- APOLLO: SLN360 Clears First Major Hurdle, Hammering Lp(A)April 3rd, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
